Paper Details

  1. Home
  2. Paper Details

Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.

Author: ErikssonM, NorrbyS R, OttossonE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the cost-effectiveness of two antibiotic regimens for treating serious bacterial infections in 118 patients. One group received imipenem/cilastatin, while the other received gentamicin plus clindamycin. While imipenem/cilastatin was more expensive per day, the overall cost of treatment, including medication, equipment, and staff, was similar to the other regimen. However, imipenem/cilastatin was more effective and had fewer side effects. The study concludes that imipenem/cilastatin was more cost-effective than gentamicin plus clindamycin in treating these patients.
Paper Details　
Original Abstract of the Article :
A previously published clinical trial was used for analysis of costs for antibiotic treatment in patients with serious bacterial infections requiring the use of injectable broad spectrum antibiotics. The patients were randomized to receive imipenem/cilastatin 500/500 mg q6h (77 patients of which 56 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/00365548609032349

データ提供：米国国立医学図書館（NLM）

Comparing Antibiotic Treatments: Cost-Effectiveness is Key

The field of infectious disease management is a constant desert of challenges, with researchers always searching for the most effective and affordable treatments. This study delves into the cost-effectiveness of two antibiotic regimens for serious bacterial infections: imipenem/cilastatin versus gentamicin/clindamycin. Researchers meticulously analyzed the costs associated with each treatment, including drug acquisition, administration, and monitoring. They discovered that imipenem/cilastatin, despite a higher drug cost, was not more expensive per treatment day than gentamicin plus clindamycin. The researchers found that imipenem/cilastatin was significantly more effective and caused fewer side effects, making it the more cost-effective option in the patients they studied.

More Than Just Cost: Effectiveness Matters

This research illuminates the critical importance of considering not just cost but also effectiveness when choosing treatments. It's like choosing a camel for a journey across the desert – you might find a cheaper camel, but if it's not strong or reliable, you'll be in trouble. The same applies to medication; an effective treatment can save money in the long run by preventing complications and hospital stays.

Cost-Effective Care: A Win-Win for Patients and Providers

This research provides valuable insights into the economic and clinical benefits of imipenem/cilastatin for patients with serious bacterial infections. It highlights the importance of choosing effective and cost-effective therapies, benefitting both patients and healthcare systems.

Dr.Camel's Conclusion

This study reminds us that choosing a treatment is not just about minimizing costs; it's about maximizing effectiveness and value. Just like selecting a sturdy camel for a desert trek, finding the right treatment for a patient can ensure a smooth and successful outcome. This research is a valuable oasis of knowledge in the vast desert of infectious disease management.

Date :
  1. Date Completed 1986-11-14
  2. Date Revised 2019-08-24
Further Info :

Pubmed ID

3094139

DOI: Digital Object Identifier

10.3109/00365548609032349

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.